---
title: "CNS Pharmaceuticals Q2 FY26 net loss widens 9% to $2.59 million year over year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295660935.md"
description: "CNS Pharmaceuticals reported a widened net loss of $2.59 million for Q2 FY26, up 9% year-over-year. Operating losses increased 12.1% to $2.7 million due to higher general and administrative expenses (+20.7%) and R&D costs (+2.9%). Interest income doubled to $116,000, while cash reserves stood at $20 million. The company is shifting strategy toward new development-stage assets and exploring out-licensing of legacy products."
datetime: "2026-08-12T11:57:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295660935.md)
  - [en](https://longbridge.com/en/news/295660935.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295660935.md)
generator: "portal-rs"
---

# CNS Pharmaceuticals Q2 FY26 net loss widens 9% to $2.59 million year over year

-   CNS Pharmaceuticals posted a net loss of $2.59 million for the quarter ended June 30, 2026, widening 9% year over year. \* Operating loss widened 12.1% to $2.7 million as total operating expenses climbed 12.1% to $2.7 million. \* General and administrative costs rose 20.7% to $1.5 million; research and development spending edged up 2.9% to $1.2 million. \* Interest income more than doubled to $116,000, lifting other income to $112,000; cash totaled $20 million at quarter-end. \* Strategy shift announced in March 2026 targets new development-stage assets, while exploring out-licensing of legacy TPI 287 and Berubicin. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-006224), on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CNSP.US](https://longbridge.com/en/quote/CNSP.US.md)

## Related News & Research

- [CNS Pharmaceuticals director Michal Fisher files initial beneficial ownership statement](https://longbridge.com/en/news/296232426.md)
- [CNS Pharmaceuticals announces annual shareholder meeting](https://longbridge.com/en/news/296654305.md)
- [Insider Move at CNS Pharmaceuticals Sparks Investor Buzz](https://longbridge.com/en/news/296299014.md)
- [CNSP: Strategic pivot targets high-value oncology and neurology assets with strong financial backing](https://longbridge.com/en/news/296126240.md)
- [Apimeds Pharmaceuticals US gains Apitox rights in assignment from South Korea’s FreeT](https://longbridge.com/en/news/296653985.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**